Pfizer Korea’s Litfulo has cleared a key reimbursement review for severe alopecia areata in adults and adolescents aged 12 and older, moving closer to national health insurance coverage. The Health Insurance Review and Assessment Service (HIRA) said its Pharmaceutical Reimbursement Evaluation…
Phase 1 assesses safety in healthy adults; Phase 2a will enroll people with MS Written by Patricia Inacio, PhD | Nov. 5, 2026 Myelin is a protective coating around nerve fibers that helps electrical signals travel efficiently. In multiple sclerosis, damage to myelin disrupts these…
If your platelet count still isn’t where it should be, your provider will revisit your treatment plan to see what needs to change Person sitting at kitchen table, reading prescription medication bottle When you first started treatment for immune thrombocytopenia…
November 05, 2026 12:17 ET | Source: Spherix Global Insights Spherix Global Insights Although perceptions of unmet need have moderated somewhat since 2025, significant opportunities remain across disease severities and patient types. Patients with moderate-to-severe HS, poor quality of life, and obesity represent higher unmet…
TG Therapeutics (NasdaqCM:TGTX) reported initial Phase 1 data for azer-cel, its allogeneic CD19-directed CAR T-cell therapy in progressive multiple sclerosis. The first-in-indication results were presented at a major international MS conference, marking the earliest clinical look at azer-cel in this…
BioSpace Amphista Therapeutics to Present AMX-883 Data at American Society of Hematology (ASH) Annual Meeting - AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia (AML) - Additional abstract on AMX-883 BRAMLIE…
In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026. Adults with late-onset progressive familial intrahepatic cholestasis (PFIC) who received odevixibat (Bylvay) in routine practice reported improved pruritus within 3 months,…
The faculty turn to the safety and practical aspects of using belantamab mafodotin, drawing on earlier experience with the drug. They discuss how lines of therapy are defined and whether the definition needs refinement, and how efficacy endpoints translate into…
iStock, sean zheng lim Novartis’ Zolgensma has faced its share of controversy. Now, the spinal muscular atrophy gene therapy is making the rounds on social media again, as patient advocates sound the alarm over tumors possibly related to the product.
- Data to be Presented at The Liver Meeting® Demonstrate Rapid and Sustained Improvements in ALP Levels with Livdelzi in Adults with PBC and ALP Levels Between 1-1.67× ULN, Despite Receiving UDCA or with Intolerance to UDCA - - Gilead Will Engage Global Regulatory…
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
An article joins this feed when it matches these terms. Each one is also a search of its own.